Stakeholder Engagement for Identifying Material Topics and Communication Frequency

The Corporate Governance Officer reports the communications with stakeholders to the Board of Directors annually. The communications with stakeholders including feedbacks from stakeholders, responses and follow-up response plans have been reported to the Board of Directors on August 7, 2024.

 

Stakeholders Main party Key Focus Areas Responses Communication Performance in 2024
Shareholders/
Investors
  • Institutional shareholders
  • Individual shareholders
  • Business Ethics
  • Legal compliance and ethical corporate
  • Operating Risk, Risk Management
  • Sustainable Governance Operations
  • Economic Performance
  • New drug R&D and innovation
  • Spokesperson and mailbox
  • Company website
  • Investor conference
  • Shareholders’ meeting
  • Board of Directors
  • ✓ Held 4 investor conferences
  • ✓ Held 1 shareholders’ meeting and 6 Board meetings
  • ✓ Shareholders exercised their voting rights by electronic means to fully participate in the voting on proposals
  • ✓ Prepared the annual report for the shareholders’ meeting and announcement for investors’ reference
Employees All Employees
  • Occupational Safety and Health Management
  • Well-being and Inclusive Workplace
  • Diversity and Equal Opportunities
  • Talent Development and Training
  • Labor-Management Relations
  • Business Ethics
  • Human Rights
  • Labor-Management meeting
  • Departmental meeting
  • Interdepartmental meeting
  • Employee Welfare Committee
  • ✓ Quarterly labor-management meetings
  • ✓ Biannual Plan of Action (POA) meetings
  • ✓ Regularly held departmental meetings(monthly)
  • ✓ Held 8 Employee Welfare Committee
  • ✓ PDP performance management interviews (initial/mid-term/final)
  • ✓ Annual Individual Development Plans (IDP) setup and feedback
Clients
  • Healthcare professionals
  • Patients
  • Agents
  • New drug R&D and innovation
  • Quality and safety management of medicines
  • Drug Distribution and Pricing
  • Customer Privacy
  • Physician-Patient Relationship and Social Participation
  • Seminars
  • Visits
  • ✓ Periodic large-scale workshops
  • ✓ Freephone number
  • ✓ Irregular meetings
  • ✓ Education and training
Suppliers and Contractors
  • Raw material suppliers
  • Outsourced manufacturers
  • Pharmaceutical warehousing and logistics
  • Transport distribution companies
  • General service suppliers
  • Business Ethics
  • Regulatory Compliance and Integrity in Operations
  • Economic Performance
  • New Drug Research and Innovation
  • Supply Chain Management
  • Emails
  • Visits
  • Production and sales meetings
  • ✓ Monthly regular meetings
  • ✓ Annual and triennial evaluations for existing suppliers
  • ✓ Auditing of new suppliers
  • ✓ Phone and email
Media outlets
  • General public
  • Economic Performance
  • New Drug Research and Innovation
  • Drug Quality and Safety Management
  • Doctor-Patient Relations & Social Engagement
  • Drug Distribution and Pricing
  • Customer Privacy
  • Visits
  • Emails
  • ✓ Irregular annual press
  • ✓ luncheons for financial disclosures
  • ✓ Occasional media visits and luncheons
  • ✓ Press releases for important announcements
  • ✓ Communication via phone and email
Competent Authorities Government
  • Climate Change
  • Chemical Substance Management
  • Ecological Impact
  • Labor/management relations
  • Legal compliance and ethical corporate management
  • Information Security
  • Air pollution management
  • Water resources management
  • Waste management
  • Official letter correspondence
  • Promotion of policies and relevant systems
  • ✓ Financial reports
  • ✓ Market Observation Post System (MOPS)
  • ✓ Irregular audits
  • ✓ Participated in awareness raising events

 

Investors and Shareholders

Spokesperson: Ted Kao

Title: Chief Financial Officer

Phone: 02-2655-8525 #5154

Email: ted_kao@tshbiopharm.com

 

Deputy Spokesperson and Investor Relations Contact: Shuping Huang

Title: Manager of Administration Department

Phone: 02-2655-8525 #5105

Email: Shupinghuang@tshbiopharm.com

 

Whistleblowing- Ethical Management Promotion Team

Email: ethical@tshbiopharm.com

 

Internal Whistleblowing

Contact: Jessica Wu

Title: Chief Internal Auditor

Phone: 02-2655-8525 #5523

Email: Jessica_wu@tshbiopharm.com

 

Collaboration

Contact: Han Hsieh

Title: Director of Corporate Development and Research

Phone: 02-2655-8525 #5412

Email: han_hsieh@tshbiopharm.com

 

Suppliers

Contact: Eliza Chang

Title: Senior Specialist

Phone: 02-2655-8525 #5131

Email: eliza@tshbiopharm.com

 

Public Relations and Sustainable Development

Contact: Isa Wang

Title: Assistant Manager

Phone: 02-2655-8525 #5111

Email: isa_wang@tshbiopharm.com